Apthera, Inc. announced the optimized dose and schedule for its lead drug, NeuVax, in treating early-stage breast cancer patients to be used in Phase III clinical trials. Dr. George Peoples, Deputy Director, United States Military Cancer Center, co-authored a publication that appears on the cover of the October 1, 2008, issue of Cancer (Vol.113 Issue 7:1666-75) and details the Phase I/II clinical study results.

A novel endoscopic-assisted technique for skin-sparing mastectomy with immediate breast reconstruction can successfully treat early breast cancer patients while offering favorable aesthetic results. Researchers of a study in

A majority of women with breast cancer today are candidates for lumpectomy, allowing for conservation of most of their breast tissue. Results of a UC Davis study, however, show that a number of women whose cancer recurs in the same breast are treated with a second lumpectomy rather than a mastectomy, defying current treatment recommendations and cutting the number of years those women survive in half.

Join the live lumpectomy surgery to remove early stage breast cancer and prepare the surgical site for IntraBeam(R), intraoperative radiation therapy that occurs right in the operating room. From Sentara CarePlex Hospital in Hampton, Virginia with surgical oncologist Dr. Richard C. Hoefer and radiation oncologists Dr. Michael Miller and Dr. Song Kang IntraBeam(R) is a registered trademark of Carl Zeiss Meditec, Inc.

Many breast cancer cells facing potentially lethal antiestrogen therapy recycle to survive, researchers say. About 70 percent of breast cancer cells have receptors for the hormone estrogen, which acts as a nutrient and stimulates their growth. Patients typically get an antiestrogen such as tamoxifen for five years to try to starve them to death, says Dr. Patricia V. Schoenlein, cancer researcher in the Medical College of Georgia Schools of Medicine and Graduate Studies.

Coinciding with the observance of Nuclear Medicine Week (October 5 to 11) and National breast cancer Awareness Month (October), SNM has released a new fact sheet highlighting recent developments in molecular imaging technologies that are dramatically improving the ways in which breast cancer is diagnosed and treated. Molecular imaging is a highly effective, safe and painless imaging tool for diagnosing and treating breast cancer.

The University of Texas M. D. Anderson Cancer Center has received nearly $19 million in grants from Susan G. Komen for the Cure® as part of that organization’s new initiative to fast-track promising research to benefit breast cancer patients. Ranging from $120,000 to $7.5 million, the grants will be allocated across 11 different translational breast cancer research studies with the intent to bring treatments from the laboratory to patient care as quickly as possible.

The American College of Obstetricians and Gynecologists (ACOG) will again serve as a national co-sponsor for National breast cancer Awareness Month (NBCAM). ACOG is proud to work with NBCAM and other organizations at the forefront of women’s health and breast cancer research to offer educational resources and services to help women prevent, detect, manage, and treat the disease. Today, there are 2.

Personal beliefs about inconclusive DNA testing for hereditary breast cancer are associated with cancer-related worry, and such beliefs are an especially strong predictor of whether women had been able to leave the period of DNA-testing behind, reports a study in the October issue of Genetics in Medicine, official journal of the American College of Medical Genetics (ACMG). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) presented data this week from preclinical studies on Angiolix showing that by blocking lactadherin, Angiolix has both an anti-angiogenic effect as well as a direct anti-proliferative effect on tumors themselves.